When Blood Disorders Meet Cancer: Uncovering the Oncogenic Landscape of Sickle Cell Disease
Open Access
- 30 November 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8509
Abstract
Sickle cell disease (SCD) is a hemoglobinopathy characterized by hemolysis, vaso-occlusion, and systemic inflammation. Epidemiological studies identified an increased risk of leukemia, especially acute myeloid leukemia (AML), in individuals with SCD, whereas data regarding other tumors are conflicting. SCD-associated AMLs frequently display high-risk features with unfavorable karyotypes and a dismal prognosis. SCD is associated with multiple phenomena linked to carcinogenesis in other contexts, including chronic inflammation, oxidative stress, ineffective erythropoiesis, accelerated hematopoietic aging, impaired tumor immunosurveillance, and increased clonal hematopoiesis. The role and respective contribution of these disease-intrinsic mechanisms in SCD remain to be studied. Although therapies used in SCD could theoretically modulate the risk of malignancies, no data exist to support an increased or reduced risk associated with their use. The most notable exception is hematopoietic stem cell transplantation and, to a lesser extent, gene therapy, for which the conditioning and/or procedure itself is known to increase the risk of leukemia. In sum, the effect of SCD on carcinogenesis is an emerging area of investigation with data supporting specificities in SCD-associated AML. Future research is required to determine the role of treatments to mitigate the increased risk and improve the outcome of SCD-associated AML.Keywords
This publication has 146 references indexed in Scilit:
- Telomere attrition in sickle cell anemiaAmerican Journal of Hematology, 2017
- Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemiaAmerican Journal of Hematology, 2015
- Management of Sickle Cell DiseaseJAMA, 2014
- Peripheral blood features of acute myeloid leukemia with myelodysplasia‐related changes developing in a patient with sickle cell anemiaAmerican Journal of Hematology, 2014
- Partial dysfunction of Treg activation in sickle cell diseaseAmerican Journal of Hematology, 2013
- Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease managementAmerican Journal of Hematology, 2011
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Malignancy in patients with sickle cell diseaseAmerican Journal of Hematology, 2003
- Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell AnemiaJAMA, 2003
- Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986-1995American Journal of Hematology, 1997